Zymeworks Inc. filed an 8-K on November 16, 2026, disclosing that its Board of Directors authorized a second 2026 share repurchase program allowing the company to repurchase up to $200.0 million of its outstanding common stock through 2028.

Key Highlights

  • New repurchase authorization: The Board authorized repurchases of up to $200.0 million of outstanding common stock under the Second 2026 Share Repurchase Program.
  • Program duration: The Second 2026 Share Repurchase Program runs through 2028, according to the filing.
  • Prior program completed: The company disclosed it has completed its initial 2026 share repurchase program, under which it was authorized to repurchase up to $125.0 million of outstanding common stock.
  • Security covered: Repurchases apply to common stock with a par value of $0.00001 per share.
  • Announcement date: The press release announcing the program was issued on November 16, 2026.

Zymeworks Board Approves Second 2026 Repurchase Program After Completing $125M Initial Authorization

According to the 8-K filed with the U.S. Securities and Exchange Commission on November 16, 2026, Zymeworks Inc. (NASDAQ:ZYME) announced that its Board of Directors authorized the Second 2026 Share Repurchase Program. Under this program, the company may repurchase up to $200.0 million of its outstanding common stock, par value $0.00001 per share, through 2028.

The filing also disclosed that the company has completed its initial 2026 share repurchase program, under which the Board had authorized repurchases of up to $125.0 million of outstanding common stock. No additional details about the timing or method of repurchases under the new program were provided in the filing itself.

The disclosure was made under Item 8.01 (Other Events) and Item 7.01 (Regulation FD Disclosure). The filing notes that the information furnished under Item 7.01 and in the accompanying press release (Exhibit 99.1) "shall not be deemed 'filed' for purposes of Section 18 of the Exchange Act." The 8-K was signed by Kenneth Galbraith, Chair, President and Chief Executive Officer of Zymeworks Inc.

What Was Disclosed

Zymeworks filed an 8-K on November 16, 2026, reporting Board authorization of a new share repurchase program of up to $200.0 million through 2028, following completion of the prior $125.0 million initial 2026 repurchase program.